Collegium Pharmaceutical Future Growth
How is Collegium Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
46.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 607 | 130 | 303 | 330 | 5 |
12/31/2024 | 598 | 134 | 322 | 316 | 5 |
12/31/2023 | 568 | 74 | 255 | 264 | 6 |
9/30/2022 | 362 | -43 | 93 | 94 | N/A |
6/30/2022 | 314 | -35 | 67 | 69 | N/A |
3/31/2022 | 273 | 43 | 56 | 58 | N/A |
12/31/2021 | 277 | 72 | 102 | 104 | N/A |
9/30/2021 | 326 | 104 | 87 | 90 | N/A |
6/30/2021 | 326 | 107 | 102 | 107 | N/A |
3/31/2021 | 321 | 42 | 115 | 121 | N/A |
12/31/2020 | 310 | 27 | -280 | 94 | N/A |
9/30/2020 | 308 | 18 | -286 | 87 | N/A |
6/30/2020 | 302 | 0 | -313 | 59 | N/A |
3/31/2020 | 299 | -13 | -341 | 30 | N/A |
12/31/2019 | 297 | -23 | 21 | 28 | N/A |
9/30/2019 | 296 | -11 | 47 | 54 | N/A |
6/30/2019 | 293 | -22 | 81 | 90 | N/A |
3/31/2019 | 291 | -30 | 123 | 131 | N/A |
12/31/2018 | 280 | -39 | 145 | 169 | N/A |
9/30/2018 | 218 | -66 | 91 | 114 | N/A |
6/30/2018 | 160 | -62 | 39 | 59 | N/A |
3/31/2018 | 90 | -70 | -34 | -14 | N/A |
12/31/2017 | 28 | -75 | -68 | -67 | N/A |
9/30/2017 | 19 | -85 | -78 | -77 | N/A |
6/30/2017 | 7 | -98 | -85 | -84 | N/A |
3/31/2017 | 4 | -102 | -90 | -87 | N/A |
12/31/2016 | 2 | -94 | -78 | -75 | N/A |
9/30/2016 | 0 | -76 | -64 | -61 | N/A |
6/30/2016 | N/A | -59 | N/A | -48 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COLL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: COLL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: COLL is expected to become profitable in the next 3 years.
Revenue vs Market: COLL's revenue (2.3% per year) is forecast to grow slower than the US market (7% per year).
High Growth Revenue: COLL's revenue (2.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if COLL's Return on Equity is forecast to be high in 3 years time